Dizal's Golidocitinib In Combination With Anti-PD-1 Shows Promise IN IO Resistant Non-Small Cell Lung Cancer
ReutersMar 20, 2025 10:50 AM
March 20 (Reuters) - Dizal Pharmaceutical Co Ltd 688192.SS:
DIZAL'S GOLIDOCITINIB IN COMBINATION WITH ANTI-PD-1 SHOWS PROMISE IN IO RESISTANT NON-SMALL CELL LUNG CANCER
DIZAL PHARMACEUTICAL CO LTD - GOLIDOCITINIB AND PD-1 ANTIBODY SHOW SYNERGISTIC EFFECTS IN NSCLC
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
SK Hynix Margin Tops TSMC as Micron Misses Out on Nvidia Orders, Is the HBM Sector Facing a Shake-Up?
Samsung, which lagged behind during the HBM3 era, has returned to the arena, while Micron, once a frontrunner, missed out on Nvidia’s orders. Is a reshuffle imminent in the HBM sector?TradingKey
14 hours ago
Strategy Defies DAT Sell-Off, Doubles Down Amid Leverage Woes
MicroStrategy acquired over 1,000 additional Bitcoins last week, with Michael Saylor stating the company will purchase Bitcoin every quarter moving forward.TradingKey
19 hours ago
Silver Faces Sixth Consecutive Year of Supply Deficit, How Much Upside Is Left in 2026?
TradingKey - According to the 2026 Silver Market Outlook recently released by the Silver Institute, the current robust performance of the silver market remains supported by solid fundamentals. The report indicates that the global silver market is expected to face a structural supply-demand imbalanceTradingKey
23 hours ago
